Warrant [Member]
Class of Warrant or Right [Axis]
Restricted Stock Units (RSUs) [Member]
Award Type [Axis]
Equity Components [Axis]
Stock Option Plan [Member]
Options Granted To Consultants [Member]
2007 Incentive Stock And Awards Plan [Member]
Range One [Member]
Exercise Price Range [Axis]
Options Granted To Employees [Member]
Tranche Four [Member]
Vesting [Axis]
Tranche Five [Member]
Lender Warrants [Member]
Related Party [Axis]
Warrants Issued In April 2012 Private Placement [Member]
Underwriter Warrants [Member]
Minimum [Member]
Range [Axis]
Maximum [Member]
Mark Baum [Member]
Title of Individual [Axis]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Tranche One [Member]
Tranche Two [Member]
Tranche Three [Member]
Consultant Tranche 1 [Member]
Consultant Tranche 2 [Member]
Consultant Tranche 3 [Member]
Consultant Tranche 4 [Member]
Consultant Tranche 5 [Member]
Warrants Issued To Investor Relations Consultant [Member]
Warrants Issued To Investor Relations Consultant [Member]
PCCA License Agreement [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
PCCA Strategic Alliance Agreement [Member]
Restricted Stock Units One [Member]
Warrant [Member]
Customer Relationships [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Trade Name [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Restricted Stock [Member]
Class of Stock [Axis]
Pharmacy Creations, LLC [Member]
Park [Member]
Business Acquisition [Axis]
Period Ending March 31, 2016 [Member]
Report Date [Axis]
Employees And Directors [Member]
Employees [Member]
Selling And Marketing [Member]
Income Statement Location [Axis]
General And Administrative [Member]
Research And Development [Member]
Directors [Member]
Consultant [Member]
Urigen Pharmaceuticals, Inc [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Dr. Robert Kammer [Member]
Baum Performance Equity Award [Member]
Monte Carlo Simulation [Member]
Plan Name [Axis]
Monte Carlo Simulation One [Member]
Non-Employee Directors [Member]
Andrew R. Boll [Member]
Former Directors [Member]
Non-Competition Clause [Member]
Stock Options [Member]
Option Indexed to Issuer's Equity, Type [Axis]
April 1, 2015 [Member]
Life Sciences Alternative Funding LLC [Member]
Loan Agreement [Member]
May 11, 2015 [Member]
Billing And Collection Agreement [Member]
Third Party [Member]
Sellers [Member]
Park Compounding [Member]
Non-Employee Director [Member]
John P. Saharek [Member]
Boll Performance Equity Award [Member]
Lease Agreement [Member]
Lease Arrangement, Type [Axis]
Sublease Agreement [Member]
Subsequent Event [Member]
Subsequent Event Type [Axis]
Dynamics Pharmacy; and Mycotoxins, LLC [Member]
Financial Instrument [Axis]
May 11, 2016 [Member]
Minimum Revenue or Cash Balance [Member]
Concentration Risk Benchmark [Axis]
12.5 Note Payable [Member]
Debt Instrument [Axis]
Transition Period [Member]
FDA [Member]
Loans Insured or Guaranteed by Government Authorities [Axis]
Asset Purchase Agreements [Member]
Other 2015 Acquisitions [Member]
Patents [Member]
Trademarks [Member]
Mr. Mark Baum [Member]
Greater Than $9.00 (the "First Price Condition) [Member]
Greater Than $10.00 (the "Second Price Condition) [Member]
Greater Than $12.00 (the "Third Price Condition) [Member]
Greater Than $14.00 (the "Fourth Price Condition) [Member]
Greater Than $15.00 (the "Fifth Price Condition) [Member]
2007 Incentive Stock and Awards Plan [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets
Cash and cash equivalents
Restricted short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Intangible assets, net
Goodwill
Furniture and equipment, net
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Customer deposits
Current portion of deferred acquisition obligation and accrued interest
Current portion of contingent acquisition obligation
Current portion of capital lease obligations
Total current liabilities
Capital lease obligations, net of current portion
Contingent acquisition obligation
Deferred acquisition obligation, net of current portion
Accrued expenses, net of current portion
Note payable and paid-in-kind interest, net of unamortized debt discount and issuance costs
TOTAL LIABILITIES
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 90,000,000 shares authorized, 9,681,646 and 9,258,231 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues:
Sales, net
License revenues
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling and marketing
General and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expense):
Interest income (expense), net
Other income
Total other income (expenses), net
Net loss
Basic and diluted net loss per share of common stock
Weighted average number of shares of common stock outstanding, basic and diluted
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment
Amortization of intangible assets
Amortization of debt issuance costs and discount
Paid-in-kind interest added to principal of note payable
Non-cash gain on contingent acquisition obligations
Stock-based compensation
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Customer deposits
NET CASH USED IN OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Park Compounding, net
Purchase of Central Allen Pharmacy, net
Purchase of restricted short-term investment
Purchase of Pharmacy Creations, LLC, net
Investment in patents and other identifiable intangible assets
Purchases of furniture and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligation
Payments on Park deferred acquisition obligation
Proceeds from note payable, net of issuance costs and fees
Net proceeds from exercise of warrants and stock options
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, beginning of period
CASH AND CASH EQUIVALENTS, end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of stock options for consulting services included in accounts payable and accrued expenses
Issuance of common stock and deferred obligations in the purchase of Park Compounding
Estimated relative fair value of warrants issued in connection with note payable
Final fee on note payable recorded as debt discount and included in accrued expenses
Purchase of furniture and equipment with a capital lease
Accounting Policies [Abstract]
Description of Business and Basis of Presentation
Summary of Significant Accounting Policies
Business Combinations [Abstract]
Acquisitions
Restricted Short-term Investments
Restricted Short-Term Investments
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Concentrations of Credit Risk
Accounts Receivable
Revenue Recognition and Deferred Revenue
Business Combinations
Goodwill and Intangible Assets
Impairment of Long-Lived Assets
Debt Issuance Costs and Debt Discount
Fair Value Measurements
Third Party Billing and Collection Agreements
Stock-Based Compensation
Income Taxes
Basic and Diluted Net Loss per Common Share
Use of Estimates
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic and Diluted Earnings Per Common Share
Schedule of Acquisition Date Fair Value of Consideration
Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed
Schedule of Result of Operation from Acquisition
Schedule of Intangible Assets Acquisition
Schedule of Pro Forma Financial Information
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Changes in Carrying Value of Goodwill
Schedule of Accounts Payable and Accrued Expenses
Summary of Notes Payable
Summary of Future Minimum Payments
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumption
Schedule of Shares Outstanding and Exercisable
Market-based Vesting Conditions for Restricted Stock Units Granted
Schedule of Restricted Stock Units Activity
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Compensation and Retirement Disclosure [Abstract]
Schedule of Lease Equipment Under Capital Lease
Net losses
Accumulated deficit
Net cash used in operating activities
Cash and cash equivalents and restricted investments
Statement [Table]
Statement [Line Items]
Deposit coverage limits by FDIC, per owner
Cash deposits in excess of FDIC limits
Accounts receivable, net of allowance for doubtful accounts
Patent estimated useful life
Impairment of long-lived assets
Percentage of billing and collection amount
Billing and collection management expense
Due to related party
Unrecognized tax benefits
Recognize interest and/or penalties related to income tax matters in income tax expense
Anti-dilutive
Number of restricted stock included in common stock equivalents
Numerator - net loss
Denominator - weighted average number of shares outstanding, basic and diluted
Net loss per share, basic and diluted
Cash paid for business acquisition, net of fees
Payment of cash remaining in bank account
Number of common stock shares sold
Number of common stock sold
Cash payment
Issuance of common stock for payment
Issuance of common stock shares for payment
Percentage of discount rate
Total acquisition date fair value
Deferred acquisition obligations
Acquisition adjusted description
Increase of goodwill
Increase of intangible assets
Business acquisition puchase price
Contingent consideration
Net tangible assets
Identifiable intangible assets
Acquisition expenses
Cash payment to the PC Sellers at closing
Restricted common stock issuance to Sellers at closing
Deferred consideration to Sellers
Total acquisition date fair value
Cash and cash equivalents
Accounts receivable
Inventories
Furniture and equipment
Intangible assets
Total identifiable assets acquired
Accounts payable and accrued expenses
Other liabilities
Total liabilities assumed
Total identifiable assets less liabilities assumed
Net assets acquired
Total revenues
Net income
Intangible Assets Fair Value
Useful Life
Total revenues
Net loss
Restricted Short-term Investments Details Narrative
Certificate of deposit
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Deposits and other current assets
Total prepaid expenses and other current assets
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Net Carrying value
Remainder of 2015
2016
2017
2018
2019
Thereafter
Intangible assets
Goodwill, Beginning
Acquisition of Park (see Note 3)
Other acquisitions (see Note 3)
Goodwill, Ending
Accounts payable
Deferred rent
Accrued exit fee for note payable (see Note 9)
Building lease liability (1)
Other accrued expenses
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Area of office space
Area of previous office space
Monthly rent amount
Recognized lease losses related to estimated remaining lease liability
Stock based compensation accrual
Additional paid-in-capital
Principal amount of loan
Debt principal amount withdrawn
Debt principal remaining amount
Achievement revenue
Loans bear interest
loans bear interest rate description
Loan installments
Percentage of loan agreement final fee
Loan due date
Incurred expenses loan
Liability of final fee included in accrued expenses
Issuance of warrants to purchase maximum number of shares
Common stock exercise price per share
Issuance of warrants to purchase of common stock expiration year
Fair value of warrants
Fair value of common stock
Common stock volatility rate
Dividend rate percentage
Risk-free interest rate percentage
Debt discount
12.5% note payable
Add: Interest paid-in-kind
Less: Discount on note for issuance costs and relative fair value of warrants
Less: Current portion
Long-term portion
Remainder of 2015
2016
2017
2018
2019
Thereafter
Total minimum payments
Less: amount representing interest and interest paid-in-kind
Note payable, gross
Add: interest paid-in-kind
Less: unamortized discount and issuance costs
Note payable and interest paid-in-kind, net of unamortized debt discount and issuance costs
Issuance of restricted common stock, shares
Issuance of restricted common stock
Issuance of common stock shares for vested awards
Number of stock option granted, shares
Issuance of common stock shares of warrant exercise
Proceeds from issuance of stock option exercise
Issuance of common stock exercise on cash basis of warrant to purchase shares
Issuance of common stock exercise on cash basis of warrant to purchase
Issuance of common stock shares for exercise
Issuance of warrant purchase of common stock exercise, shares
Common stock exercise price per share
Purchase of stock option during period
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Maximum number of common stock issuance under the plan
Common stock market price per share
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Percentage of forfeiture factor
Unrecognized compensation expense related to unvested stock options granted under the Plan
Expense expected to recognize over the weighted-average remaining vesting period
Weighted Avg. Exercise Price, Options exercised
Vested option outstanding
Intrinsic value of stock option exercised
Number of stock option granted
Stock option targeted price range lower limit
Stock option targeted price range upper limit
Stock option period
Initial fair value of stock option
Fair value assumptions, life term
Fair value assumptions, volatility
Fair value assumptions, risk free interest rate
Risk-free interest rate
Intrinsic value of warrants exercised
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest - end of period
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility
Expected volatility, minimum
Expected volatility, maximum
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of Shares
Target Share Price
Number of RSUs, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number of RSUs cancelled/forfeited
Number of RSUs, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited
Weighted Average Grant Date Fair Value, Ending balance
Number of shares, Outstanding, Beginning balance
Number of Shares Subject to Warrants Outstanding, Granted
Number of Shares Subject to Warrants Outstanding, Exercised
Number of Shares Subject to Warrants Outstanding, Expired
Number of shares, Outstanding, Ending balance
Weighted Average Remaining Contractual Life Of The Outstanding Warrants In Years
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Granted
Weighted Avg. Exercise Price, Exercised
Weighted Avg. Exercise Price, Expired
Weighted Avg. Exercise Price, Outstanding, Ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Stock based compensation related to equity instruments granted to related parties
Leases equipment under capital lease with interest rate
Equipment under capital leases net
Related accumulated depreciation
Lease agreement for office space (Square feet)
Operating lease Expiry
Operating lease, monthly rental
Operating lease, rent increase percentage
Rent expense
License agreement commitments description
Minimum royalties to be paid each calendar year
Value of product development investment
Lease term
Royalty revenue
Lease renewal term
Royalty amount
Royalties range percentage
Maximum aggregate value of cash fees
Remainder of 2015
2016
2017
Total minimum lease payments
Less amount representing interest
Present value of future minimum lease payments
Less current portion
Capital lease obligation, net of current portion
Maximum percentage of sales derived from single customer
Percentage of drug and chemical purchases from three main suppliers
Amount paid for acquired
Achievement revenue.
Acquisition adjusted description.
Acquisition Of Related Party Goodwill.
Aggregate Value Of Cash Fees
Andrew R Boll [Member]
April One Two Thousand Fifteen [Member]
Asset Purchase Agreements [Member]
Baum Performance Equity Award [Member]
Billing And Collection Agreement [Member]
Billing And Collection Management Expense.
Boll Performance Equity Award [Member]
Building Lease Liability.
Common stock exercise price per share.
Consultant
Consultant Tranche Five [Member]
Consultant Tranche Four [Member]
Consultant Tranche One [Member]
Consultant Tranche Three [Member]
Consultant Tranche Two [Member]
loans bear interest rate description.
Deferred Acquisition Obligation And Accrued Interest Current.
Deferred Acquisition Obligation Noncurrent.
Deferred Acquisition Obligations.
Deferred Consideration To Related Party.
Dr Robert Kammer [Member]
Employees And Directors [Member]
Employees [Member]
Final fee on note payable recorded as debt discount and included in accrued expenses.
First Price Condition [Member]
Former Directors [Member]
Gain On Contingent Acquisition Obligations.
General And Administrative [Member]
Initial Fair Value Of Stock Option.
Interest paid-in-kind.
Issuance Of Common Stock And Fair Value Of Deferred Acquisition Obligations Related To Purchase Of Business.
Issuance of common stock exercise on cash basis of warrant to purchase shares.
Issuance of common stock exercise on cash basis of warrant to purchase.
Issuance Of Warrant Purchase Of Common Stock Exercise Shares.
Issuance of warrants to purchase of common stock expiration year.
John .P Saharek [Member]
Lease Agreement [Member]
Leases Equipment Under Capital Lease With Interest Rate.
Lender Warrants [Member]
License agreement commitments description.
Life Sciences Alternative Funding LLC [Member]
Loan Agreement [Member]
Debt principal amount withdrawn.
Debt principal remaining amount.
Mark Baum [Member]
Maximum deposit coverage limits.
May Eleven Two Thousand Fifteen [Member]
May Eleven Two Thousand Sixteen [Member]
Minimum Revenue Or Cash Balance [Member]
Monte Carlo Simulation [Member]
Monte Carlo Simulation One [Member]
Non Competition Clause [Member]
Non Employee Director [Member]
Non Employee Directors [Member]
Number Of Shares Tied To Target.
Options granted to employees
Options granted to consultants
PCCA License Agreement [Member]
PCCA Strategic Alliance Agreement [Member]
Park Compounding [Member]
Park [Member]
Payment Of Cash Remaining In Bank Account.
Cash paid for business acquisition, net of fees.
Percentage of billing and collection amount.
Percentage of discount rate.
Percentage of drug and chemical purchases from three main suppliers.
Percentage of forfeiture factor.
Percentage of loan agreement final fee.
Period Ending March 31, 2016 [Member]
Pharmacy Creations Llc [Member].
Previous Office Space Area.
Range five [member]
Range four [member].
Range one [member].
Range three [member].
Range two [member].
Recently Adopted Accounting Pronouncements {PolicyTextBlock}
Recognized lease losses related to estimated remaining lease liability.
Research And Development [Member]
Restricted Common Stock Issuance To Related Party.
Number of restricted stock included in common stock equivalents.
Restricted Stock Units RSU One [Member].
Royalties Range Percentage
Schedule Of Marketbased Vesting Conditions Further [Table Text Block]
Schedule Of Prepaid Expenses And Other Current Assets [TableTextBlock].
Schedule of Result of Operation from Acquisition [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Sellers [Member]
Selling And Marketing [Member]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
Share Based Compensation Award Tranche Five [Member]
Share Based Compensation Award Tranche Four [Member]
Warrants Exercisable
Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term
Stock Issued During Period Shares Issued For Payment.
Stock Issued During Period Shares Warrant Exercised.
Stock Issued During Period Value Issued For Payment.
StockOptionPlanMember
Sublease Agreement [Member]
Summary of Future Minimum Payments [Table Text Block].
Target Share Price
Third Party Billing And Collection Agreements [Policy Text Block]
Third Party [Member]
Transition Period [Member]
12.5 Note Payable [Member]
2007 Incentive Stock And Awards Plan [Member]
U.S. Food And Drug Administration [Member]
Underwriter Warrants [Member].
Urigen Pharmaceuticals Inc [Member]
Value of product development investment.
Warrant
Warrants Expiration Date.
Warrants Issuance Date.
Warrants Issued In April Two Thousand Twelve Private Placement [Member]
Warrants Issued To Investor Relations Consultant One [Member]
Warrants Issued To Investor Relations Consultant Two [Member]
Second Price Condition [Member]
Third Price Condition [Member]
Fourth Price Condition [Member]
Fifth Price Condition [Member]
Investment in patents and other identifiable intangible assets.
Purchase of furniture and equipment with a capital lease.
Other Two Thousand FiFteen Acquisitions [Member].
Other Acquisitions Of Related Party Good Will.
Purchase Of Stock Option During Period.
Mr Mark Baum [Member].
Dynamics Pharmacy And Mycotoxins LLC [Member].
Business acquisition puchase price.
Debt Interest And Interest Paid in kind.
2007 Incentive Stock and Awards Plan [Member]
WarrantsIssuedToInvestorRelationsConsultantTwoMember
WarrantActivityMember
NonCompetitionClauseMember
Assets, Current
Assets
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Revenue, Net
Health Care Organization, Medical Supplies and Drugs Expense
Gross Profit
Operating Costs and Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
GainOnContingentAcquisitionObligations
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Customer Deposits
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Restricted Investments
InvestmentInPatentsAndOtherIdentifiableIntangibleAssets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt and Capital Lease Obligations
Payments of Financing Costs
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Inventory Disclosure [Text Block]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Business Acquisition, Pro Forma Revenue
Business Acquisition, Pro Forma Net Income (Loss)
Accounts Payable and Accrued Liabilities
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
Long-term Debt, Maturities, Repayments of Principal after Year Five
CommonStockExercisePricePerShare
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
Capital Leases, Future Minimum Payments, Remainder of Fiscal Year
Capital Leases, Future Minimum Payments Due, Next Twelve Months
Capital Leases, Future Minimum Payments Due in Two Years
Capital Leases, Future Minimum Payments Due
Capital Leases, Future Minimum Payments, Interest Included in Payments
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments